Asset profile
GR-MD-02
Protein / enzyme therapeutic
Evidence outlook · results not reported
NAVIGATE (NCT04365868) · MASH / NASH
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NAVIGATE (NCT04365868): This randomized, double-blind, placebo-controlled trial tested whether belapectin could prevent new esophageal varices from developing in patients with NASH cirrhosis over 78 weeks. Somewhat fewer patients on belapectin developed new varices than on placebo, but the registry does not report a statistical comparison for this result, and the sponsor halted the trial after this stage instead of continuing into the planned larger Phase 3 portion.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
32 competitors in this universe: 1 direct rival (same mechanism and indication), 2 same-class, 29 same-indication; 11 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| GR-MD-02: this drug | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| Belapectin | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| TB006 | Phase 2 | Monoclonal antibody | Galectin-3 | ||
| SIF001 | Phase 1 | Monoclonal antibody | Galectin-3 | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| ALN-HSD | Phase 2 | RNA / oligonucleotide | HSD17B13 |
…and 17 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.